Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/23/2026

1. USO
2. DHR
3. AMD
4. NVDA
5. SPY
6. GM
7. SMCI
8. GOOGL
9. TSLA
10. NOW

Go back to Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer
(NASDAQ: RVMD) Delayed: 183.03 -0.26 (0.14%)
Previous Close $183.29    52 Week High $ 
Open $180.66    52 Week Low $ 
Day High $185.40    P/E N/A 
Day Low $180.11    EPS $ 
Volume 888,757